BidaskClub Lowers GW Pharmaceuticals PLC- (NASDAQ:GWPH) to Sell

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Saturday, BidAskClub reports.

Several other equities research analysts have also commented on GWPH. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $174.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Wednesday. Needham & Company LLC began coverage on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 21st. They set a “buy” rating and a $200.00 price target for the company. Cowen reaffirmed a “buy” rating and set a $200.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Friday, July 26th. Oppenheimer reduced their price target on shares of GW Pharmaceuticals PLC- to $222.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of GW Pharmaceuticals PLC- in a research report on Friday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $198.00.

NASDAQ GWPH opened at $109.41 on Friday. GW Pharmaceuticals PLC- has a 52 week low of $90.14 and a 52 week high of $196.00. The firm has a market capitalization of $4.16 billion, a P/E ratio of -10.36 and a beta of 2.28. The company has a quick ratio of 7.59, a current ratio of 8.31 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average price of $122.70 and a 200-day moving average price of $154.23.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.74) by $0.96. GW Pharmaceuticals PLC- had a negative net margin of 26.80% and a negative return on equity of 23.44%. The firm had revenue of $72.04 million during the quarter, compared to analyst estimates of $37.28 million. During the same quarter in the prior year, the firm earned ($0.25) EPS. The business’s revenue for the quarter was up 2096.3% compared to the same quarter last year. As a group, equities research analysts anticipate that GW Pharmaceuticals PLC- will post -3.53 EPS for the current year.

In related news, insider Douglas B. Snyder sold 5,424 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $13.04, for a total transaction of $70,728.96. Following the completion of the transaction, the insider now directly owns 73,740 shares in the company, valued at approximately $961,569.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Douglas B. Snyder sold 3,756 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $13.88, for a total value of $52,133.28. Following the transaction, the insider now owns 79,164 shares of the company’s stock, valued at $1,098,796.32. The disclosure for this sale can be found here. Insiders own 3.60% of the company’s stock.

Several large investors have recently made changes to their positions in GWPH. Point72 Asset Management L.P. grew its stake in shares of GW Pharmaceuticals PLC- by 1,837.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 670,511 shares of the biopharmaceutical company’s stock valued at $115,589,000 after acquiring an additional 635,895 shares during the period. ETF Managers Group LLC bought a new position in GW Pharmaceuticals PLC- in the 2nd quarter worth approximately $99,346,000. Victory Capital Management Inc. boosted its stake in GW Pharmaceuticals PLC- by 82.7% in the 2nd quarter. Victory Capital Management Inc. now owns 747,015 shares of the biopharmaceutical company’s stock worth $128,778,000 after purchasing an additional 338,075 shares during the period. Nuveen Asset Management LLC bought a new position in GW Pharmaceuticals PLC- in the 2nd quarter worth approximately $32,687,000. Finally, Marshall Wace North America L.P. boosted its stake in GW Pharmaceuticals PLC- by 47.1% in the 2nd quarter. Marshall Wace North America L.P. now owns 466,062 shares of the biopharmaceutical company’s stock worth $80,345,000 after purchasing an additional 149,163 shares during the period. Institutional investors own 82.89% of the company’s stock.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: Front-End Load

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.